title: [Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis].
abstract: OBJECTIVE
  Due to the amount and variability in quality regarding the use of biologic therapy (BT) in patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA) patients, the Spanish Society of Rheumatology has promoted the generation of recommendations based on the best evidence available. These recommendations should be a reference for rheumatologists and those involved in the treatment of patients with spondyloarthritis (SpA), except for psoriatic arthritis (PsA), who are using, or about to use BT.
  
  
  METHODS
  Recommendations were developed following a nominal group methodology and based on systematic reviews. The level of evidence and grade of recommendation were classified according to the model proposed by the Center for Evidence Based Medicine at Oxford. The level of agreement was established through Delphi technique.
  
  
  RESULTS
  We have produced recommendations on the use of BT currently available for SpA (but not PsA) in our country. These recommendations include disease assessment, treatment objectives, therapeutic scheme and switching.
  
  
  CONCLUSIONS
  We present an update on the SER recommendations for the use of BT in patients with SpA, except for PsA.
authors.affiliation: Servicio de Reumatología, Hospital Universitari de Bellvitge, IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Juanola Roura
authors.forename: Pedro
authors.initials: P
authors.lastname: Zarco Montejo
authors.forename: Jesús
authors.initials: J
authors.lastname: Sanz Sanz
authors.forename: Santiago
authors.initials: S
authors.lastname: Muñoz Fernández
authors.forename: Juan
authors.initials: J
authors.lastname: Mulero Mendoza
authors.forename: Luis Francisco
authors.initials: LF
authors.lastname: Linares Ferrando
authors.forename: Jordi
authors.initials: J
authors.lastname: Gratacós Masmitja
authors.forename: Rosario
authors.initials: R
authors.lastname: García de Vicuña
authors.forename: Cristina
authors.initials: C
authors.lastname: Fernandez Carballido
authors.forename: Eduardo
authors.initials: E
authors.lastname: Collantes Estevez
authors.forename: Enrique
authors.initials: E
authors.lastname: Batlle Gualda
authors.forename: Rafael
authors.initials: R
authors.lastname: Ariza Ariza
authors.forename: Estíbaliz
authors.initials: E
authors.lastname: Loza Santamaría
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods / Q000592:standards*; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D025241:Spondylarthritis / Q000145:classification / Q000188:drug therapy*; D012460:Sulfasalazine / Q000008:administration & dosage / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D012460:Sulfasalazine; C529000:golimumab; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept; D008727:Methotrexate